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Abstract  
Introduction: Chondrocytes experience a hypertonic environment compared to plasma (280 
mOsm) due to the high fixed negative charge density of cartilage. Standard isolation of chondrocytes 
removes their hypertonic matrix, exposing them to non-physiological conditions. During in-vitro 
expansion, chondrocytes quickly lose their specialized phenotype, making them inappropriate for cell-
based regenerative strategies. We aimed to elucidate the effects of tonicity during isolation and in-vitro 
expansion on chondrocyte phenotype.  
 
Methods: Human articular chondrocytes were isolated and subsequently expanded at control 
tonicity (280 mOsm) or at moderately elevated, physiological, tonicity (380 mOsm). The effects of 
physiological tonicity on chondrocyte proliferation and chondrogenic marker expression were evaluated.  
The role of Tonicity-responsive Enhancer Binding Protein (TonEBP/NFAT5) in response to physiological 
tonicity was investigated using nuclear factor of activated T-cells 5 (NFAT5) RNA interference. 
 
Results: Moderately elevated, physiological, tonicity (380 mOsm) did not affect chondrocyte 
proliferation, while higher tonicities inhibited proliferation and diminished cell viability. Physiological tonicity 
improved expression of chondrogenic markers and NFAT5 and its target genes, while suppressing 
dedifferentiation marker collagen type I and improving type II/type I expression ratios >100-fold. Effects of 
physiological tonicity were similar in osteoarthritic and ‘normal’ (non-osteoarthritic) chondrocytes, indicating 
a disease-independent mechanism. NFAT5 RNA interference abolished tonicity-mediated effects and 
revealed that NFAT5 positively regulates collagen type II expression, while suppressing type I. 
 
Conclusions: Physiological tonicity provides a simple, yet effective, means to improve 
phenotypical characteristics during cytokine-free isolation and in-vitro expansion of human articular 
chondrocytes. Our findings will lead to the development of improved cell-based repair strategies for 
chondral lesions and provides important insights into mechanisms underlying osteoarthritic 
progression. 
   3
Introduction 
Hyaline articular cartilage is a connective tissue covering the ends of bones in joints and is 
composed of specialized cells, chondrocytes that produce a large amount of extracellular matrix.  This 
matrix is crucial for the unique biomechanical properties of this tissue and is composed of a collagen 
fiber network, providing tensile strength and flexibility, and abundant ground matrix rich in 
proteoglycans [1]. The glycosaminoglycan (GAG) side chains of the proteoglycans are sulfated and 
responsible for a characteristic high fixed negative charge density [2] which binds mobile cations 
(mainly sodium). This determines the physiological tonicity (i.e. osmotic pressure) of the extracellular 
fluid around chondrocytes in vivo, but the tonicity indirectly also largely depends on the quality of the 
collagen network. Extracellular tonicity in healthy cartilage ranges between 350 and 480 mOsm [3, 4]. 
In vivo, tonicity of the extracellular fluid is dynamic and changes due to alterations in matrix hydration 
[5]. During cartilage degeneration, i.e. in osteoarthritis (OA), collagen matrix degrades and GAG 
concentration diminishes, resulting in a severity-depending decreased tonicity of between 280 and 350 
mOsm [3, 6]. Currently, chondrocyte isolation and in-vitro expansion culture are performed in medium 
of non-physiological tonicity (270±20 mOsm). Several studies already showed that chondrocytes are 
tonicity responsive [7-9] and react with changes in matrix synthesis [4, 8, 10, 11], but focused on 
aggrecan (AGC1) core protein mRNA levels, AGC1 promoter activity and GAG production. 
Molecular mechanisms involved in the hypertonic response of human articular chondrocytes 
(HACs) are poorly understood. Hypertonicity perturbs cells by causing osmotic efflux of water, 
resulting in cell shrinkage [12, 13]. Cells react by a rapid uptake of ions, which increase cellular ionic 
strength [14] with potentially detrimental effects [15-17]. The initial, rapid response is the activation of 
transporters that exchange these ions for compatible osmolytes [16, 18]. This process is controlled by 
Tonicity-responsive Enhancer Binding Protein (TonEBP/NFAT5) which mediates transcriptional 
activation of these transporters [16]. NFAT5 is a member of the Rel family of transcription factors [19] 
and targets sodium/myo-inositol cotransporter (SMIT) [20, 21], sodium/chloride coupled acid 
transporters (BGT1/SLC6A12) [20], aquaporin channels (AQP1 and -2) [22], and calcium-binding 
proteins (S100A4) [23-25]. Upon hypertonic stress, transcription of NFAT5 itself is up-regulated 
several cell types [26-28], but the tonicity threshold and cell signaling pathways required to activate 
NFAT5 may be cell type specific [29]. Currently, nothing is known about the expression or function of 
NFAT5 in HACs.  
   4
 Chondral lesions by e.g. trauma or overuse, can cause joint pain, immobility and eventually 
osteoarthritis (OA). The associated high prevalence (60% of all patients undergoing knee arthroscopy 
is diagnosed with a chondral lesion [30]) and loss of quality of life makes cartilage damage a major 
personal and economical burden. Treatment options of chondral lesions are limited and autologous 
chondrocyte implantation (ACI) is the currently most developed hyaline repair technique for the knee 
[31]. Lately, characterized chondrocyte implantation (CCI), employing a phenotypical pre-screening 
prior to implantation, improved structural repair [32]. Chondrocyte dedifferentiation during in-vitro 
expansion for ACI is detrimental, but almost inevitably in standard monolayer culture: spherical 
chondrocytes will gradually convert into fibroblast-like cells [33, 34]. This morphological change is 
accompanied by a shift in collagen expression towards less collagen type II (COL2) and more collagen 
type I (COL1) [34, 35]. Consequently, dedifferentiated chondrocytes produce fibrocartilage in vivo, with 
an extracellular matrix of inferior biomechanical properties due to higher collagen (especially type I) 
content and less proteoglycans compared to hyaline cartilage [36]. Three-dimensional culture systems 
can partially prevent dedifferentiation, but are labor intensive and essentially impair propagation. 
Chondrocyte dedifferentiation might also play a role in the pathogenesis of osteoarthritis (OA), as the 
ability of aging chondrocytes to produce and repair the extracellular matrix is compromised [37] and 
collagen type I is shown to be present in clusters of fibrillated areas in late stage OA, while it is absent 
in healthy cartilage [38]. 
Here we report that physiological tonicity (380 mOsm) during isolation and monolayer 
expansion can suppress chondrocyte dedifferentiation and that expression of the extracelluar matrix 
components collagen types I and II as well as aggrecan is NFAT5-dependent. We further show that 
NFAT5 contributes to the differential regulation of both collagen types. This study provides a simple, yet 
novel and effective, means to improve cell-based repair strategies for chondral lesions and contribute 
to our understanding of osteoarthritic progression. 
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Materials and Methods 
Cartilage and chondrocyte isolation.  
After informed consent was obtained, human articular cartilage was explanted from 
macroscopically normal areas of the femoral condyles and tibial plateau of nine patients undergoing 
total knee replacement surgery for OA (medical ethical approval MEC2004-322). In addition to 
preparation of cartilage explants and isolation of human articular chondrocytes (HACs) under standard 
conditions (DMEM, 280 mOsm) as described by Das et al. [39], medium tonicity was also adjusted to 
380, 480 or 580 mOsm, respectively by addition of sterile NaCl. Enzymatic digestion, removal of 
undigested fragments and subsequent chondrocyte culture are reported earlier [39]. The 280 and 380 
mOsm isolations were also performed with cartilage obtained from the femoral condyles and tibial 
plateau of two non-OA donors (further referred to as ‘normal’ donors), undergoing above-knee 
amputation surgery after trauma. 
 
Chondrocyte proliferation and DNA measurements.  
Primary (passage 0; P0), P1, P2 and P3 HACs were monolayer expanded in medium 
corresponding to their isolation tonicity (280, 380, 480 or 580 mOsm), with an initial seeding density of 
6,000 cells/cm2. Cells were harvested daily for cell counts and DNA assay between day two and day six. 
Experiments were performed in duplicate from three OA donors (n=6). At each passage, growth curves 
were established by cell counts using Trypan Blue (Sigma, cat. T8154) and DNA quantification. DNA 
measurements were performed according to Karsten et al. [40]  with slight modifications [41].  
Doubling times within each passage were calculated from the trend line of the exponential growth 
phase using equation y = x(0) exp(kx(t)) with k = ln 2 / T (k = growth constant, T = doubling time).  
 
Chondrocyte expansion.  
Primary HACs were cultured for expansion in monolayer at a seeding density 7,500 cells/cm2  
in medium corresponding to their isolation tonicity (280, 380, 480 or 580 mOsm). Primary through P3 
cells were seeded in high-density monolayers (20,000 cells/cm2) and cultured for additional five and 
seven days before analysis of mRNA (quantitative RT-PCR) and protein expression (Western Blotting) 
respectively. Experiments were performed in triplicate from four OA donors (n=12). Additionally, 
experiments were performed in triplicate from two healthy donors (n=6), to investigate whether the 
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hypertonic stress response is specific for pathologically altered cells. To exclude sodium or chloride specific 
effects, we performed experiments using NMDG-Cl or sucrose to adjust medium tonicity to 380 mOsm. 
 
Lentiviral NFAT5 gene knock-down.  
We used lentiviral vectors for non-transient shRNA-mediated gene silencing in primary 
chondrocytes [42]. BamHI/MunI restriction fragments of the parental pLKO.1-puro vector, each 
containing the U6 promotor and one out of five different, sequence-verified anti-human NFAT5 
shDNAs (MISSION shRNA library [43]) were subcloned into corresponding restriction sites of recipient 
vector pRRL.PPT.PGK.GFPpre. This was kindly provided by L. Naldini (San Raffaele Telethon 
Institute for Gene Therapy, Milano, Italy) [44, 45] and optimized by A. Schambach (Department of 
Experimental Hematology, Hannover Medical School, Hannover, Germany) [46] to express eGFP from 
the phosphoglycerate kinase promoter. Lentiviral particles were produced in HEK293T cells by 
transient transfection using a calcium phosphate protocol [47]. Cells transduced with a lentiviral vector 
lacking the NFAT5-specific shRNA expression cassette served as controls. All cells were grown in 
monolayer. TRCN0000020020 was identified as best performing anti-NFAT5 shRNA clone by QPCR-
based knock-down efficiency determination and used in subsequent experiments. 
Passage 1 OA-HACs from two donors were seeded (15,000 cells/cm2) and cultured for four 
days in control medium (280 mOsm). Three hours prior to transduction, cells were deprived of 
antibiotics, transduced for ± 18 hours, refreshed with control medium with antibiotics and cultured for 
additional four days before harvesting for FACS analyses. Cells were resuspended in PBS with 10% 
FCS and antibiotics and washed. Cells were collected and stained with Hoechst 33258 (1 mg/mL, 
Molecular Probes) to discriminate between dead and live cells. FACS was performed on FACSAria 
(Becton Dickinson) and eGFP expressing cells were collected (>50%, MOI~1) and re-analyzed for 
purity (> 95%) using Cell Quest Pro Software.  
 EGFP expressing populations were seeded (10,000 cells/cm2) and cultured in control medium 
up to 80% confluency. Cells were then switched to medium of 380 mOsm or kept on control medium 
for 24 hours prior to RNA analysis.  
 
 
RNA expression analysis.  
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RNA isolation, purification, quantification and cDNA synthesis are described elsewhere [48]. 
Expression levels of aggrecan (AGC1), SOX9 and collagen type II (COL2) were studied as chondrogenic 
markers, while collagen type I (COL1) was studied as dedifferentiation marker [34, 35, 49, 50]. QPCR 
assays for COL2, SOX9, AGC1 and COL1 were reported earlier [51]. To quantify expression of NFAT5 and 
its target genes, the following primers were tested for similar amplification efficiency and specificity 
according to Das et al. [39] and used as 20µL SYBR® Green I reactions: HsNFAT5_Fw, 
GGGTCAAACGACGAGATTGTG, HsNFAT5_Rv, TTGTCCGTGGTAAGCTGAGAA; HsS100A4_Fw, 
GTCCACCTTCCACAAGTACTCG, HsS100A4_Rv, TCATCTGTCCTTTTCCCCAAG; HsSLC6A12_Fw, 
ACACAGAGCATTGCACGGACT, and HsSLC6A12_Rv, CCAGAACTCGTCTCTCCCAGAA). Data 
were normalized to an index of three reference genes (GAPDH, UBC, HPRT1) which were pre-evaluated 
to be stably expressed across samples [39]. Relative expression was calculated according to 2-∆CT method 
[52]. 
 
Western Blot analysis. 
Cells seeded at high densities were washed twice with PBS and lysed in RIPA buffer [53] with 
addition of protease inhibitors. Total protein concentration was quantified by BCA assay according to 
the manufacturer’s protocol (Pierce, #23225). Ten µg aliquots were subjected to 10% SDS-
polyacrylamide gel electrophoresis (PAGE) prior to electro-blotting onto nitrocellulose membranes 
(Protran BA83, Schleicher & Schuell). Blots were blocked in 5% low-fat dry milk in 1X PBS, 0.05% v/v 
NP-40, incubated with primary antibodies (anti-type II collagen and anti-type I collagen (both 1:100, 
SouthernBiotech, or 1:10,000 anti-α-Tubulin (Sigma)), washed, incubated with secondary antibodies 
(both 1:1,000, Dako Cytomation) and chemiluminescently detected. Signals were quantified using 
ImageJ 1.42 software.  
 
Statistics.  
Statistical analysis was performed using SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). Data were 
compared between groups by Kruskall-Wallis H test and post-hoc Mann–Whitney U test. Results represent 
mean ± standard deviation and p<0.05, p<0.01 and p<0.001 were considered to indicate levels of 
statistically significant difference.   
   8
Results 
Hypertonicity influences proliferation and survival of chondrocytes. 
We first determined the influence of tonicity on proliferation: osteoarthritic HACs (OA-HACs) 
isolated at 580 mOsm hardly attached nor proliferated (Figure 1; photo D) and two days after seeding no 
viable cells were recovered. At 280, 380 and 480 mOsm, respectively, cells did adhere but increasing 
tonicity induced marked morphological changes: at 280 mOsm, cells appeared fibroblast-like stretched-out 
and flattened with long filopodia (Figure 1; photo A), while at 380 mOsm cells were more sphere-shaped 
and had shorter filopodia (Figure 1; photo B). At 480 mOsm, cells showed few filopodia and appeared 
spherical (Figure 1; photo C). The differences in appearance remained throughout dedifferentiation period 
(P0 to P3), but were most apparent at earlier passages.  
Using cell counts and DNA assays, doubling times were calculated from growth curves established 
from each passage at three different tonicities (280, 380 and 480 mOsm). Throughout dedifferentiation, 
OA-HACs isolated at 480 mOsm showed severely inhibited proliferation compared to cells at 280 and 380 
mOsm (Table 1). In contrast, doubling times of OA-HACs at 280 and 380 mOsm never significantly differed 
(Table 1). Therefore, all further experiments were performed at 380 mOsm (as high tonicity condition) 
and compared to 280 mOsm (control condition).   
 
Isolation and expansion of chondrocytes under hypertonic conditions improves their phenotype. 
 Next, we set out to determine whether expansion culture in physiological tonicity improves the 
chondrocytic phenotype. Physiological tonicity (380 mOsm) during isolation and subsequent passaging of 
OA-HACs significantly increased mRNA levels of both AGC1 (Figure 2A) and SOX9 (Figure 2B) at all 
passages. In expanded P3 chondrocytes in physiological culture, AGC1 levels were still higher than in 
unpassaged P0 chondrocytes cultured under the standard culture conditions (280 mOsm). Physiological 
tonicity also significantly up-regulated COL2 levels from 8.5-fold in P0 to 11.6-fold in expanded P3 
chondrocytes (Figure 2C) compared to controls. In contrast, COL1 expression was significantly suppressed 
in physiological conditions throughout culture. Consequently, we found a significantly improved 
COL2/COL1 ratio during chondrocyte expansion (Figure 2D), from 7-fold in P0 cells to 100-fold in 
expanded P3 cells. Physiological tonicity also up-regulated COL2 protein expression (Figure 2E): levels 
significantly increased (between 1.5- and 2.2-fold) in P0, P1 and P2 chondrocytes. In contrast, physiological 
tonicity significantly decreased COL1 protein expression (Figure 2F), from 2-fold in P0 cells to 13-fold in P1 
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cells. Physiological tonicity also significantly increased AGC1 (Figure 3A) and SOX9 (Figure 3B) mRNA 
levels in non-osteoarthritic HACs (NHACs). Furthermore, COL2 mRNA levels were significantly up-
regulated; from 5.8-fold in P0 cells to 270-fold in expanded P3 NHACs (Figure 3C). Like in OA-HACs, 
hypertonicity also down-regulated COL1 expression with increasing passage number in NHACs: the 
COL2/COL1 ratios increased during expansion (Figure 3D); from 6.8-fold in P0 cells to 355-fold in 
expanded P3 cells. Correspondingly, COL2 protein levels increased under these conditions (4.8-fold in P1 
cells and 2.9-fold in P2 cells), while the amount of COL1 diminished (by 4.7-fold in P1 cells and 5-fold in P2 
cells; Figure 3E, F).  
  
Hypertonicity activates NFAT5 in human articular chondrocytes. 
Compared to 280 mOsm controls, NFAT5 mRNA levels were significantly increased in 380 mOsm 
OA-HACs cultures (Figure 4A), as was the expression of established NFAT5 target genes S100A4 (in all 
passages; Figure 4B) and SLC6A12 (until P2; Figure 4C). Similar effects were found in NHACs (data not 
shown). 
 
NFAT5 knockdown inhibits hypertonicity-induced chondrogenic marker expression. 
 Upon transduction, sorted eGFP co-expressing OA-HACs were switched to 380 mOsm for 24 
hours. In controls, not expressing NFAT5-specific shRNAs, a ~2-fold increase in NFAT5 mRNA levels was 
observed (Figure 4A; P1) upon hypertonic stimulation. In contrast, likewise challenged cells expressing 
anti-NFAT5 shRNAs showed a ~75% reduction in NFAT5 levels (Figure 5A). Following NFAT5 knockdown, 
also the NFAT5 targets, S100A4 and SLC6A12, were no longer hypertonically inducible: S100A4 
expression decreased 2-fold and SLC6A12 was virtually undetectable upon NFAT5 RNAi (Figure 5A), 
confirming a functional NFAT5 knockdown. At 380 mOsm, NFAT5 RNAi also down-regulated chondrogenic 
markers: AGC1 by 80%, SOX9 by 32% and COL2 by 84% as compared to non-RNAi controls (Figure 5B). 
Interestingly, expression of COL1 increased after NFAT5 RNAi in OA-HACs to ~300% of control levels 
(Figure 5B). 
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Discussion 
 Isolation and expansion of adult human articular chondrocytes under physiological tonicity 
(380 mOsm) improves expression of chondrogenic markers on mRNA and protein level. While other 
studies partially confirm that non-human chondrocytes respond to tonicity with altered aggrecan and 
SOX9 expression [4, 8, 10], we are reporting beneficial effects of isolating and expanding human 
normal and osteoarthritic articular chondrocytes at physiological levels (380 mOsm). In addition, we 
also studied collagen type II expression, generally acknowledged to be the most important 
chondrogenic marker. As fibrocartilaginous collagen type I and hyaline collagen type II expression are 
differentially regulated in chondrocytes [34], analyzing the collagen type II/type I expression ratios is 
informative of chondrogenic potential [51]. Interestingly, NFAT5 seems to be crucially involved in this 
differential regulation upon hypertonic challenge: it positively regulates collagen type II, while suppressing 
collagen type I (Figure 5B). Fibrocartilage, occurring in areas subject to frequent stress like intervertebral 
discs and tendon attachment sites, is more rich in collagen type I than hyaline cartilage [54]. Tonicity may 
thus provide a simple means to manipulate expression of these two collagens for broader applications 
than regenerative chondrocyte implantations (ACI or CCI) alone [55].  
 Under our conditions, COL2 mRNA abundances measured by QPCR nicely correlated with 
protein synthesis as determined by Western Blots (Figure 2 and 3). The same holds for COL1 
expression in the early passages, but not for COL1 expression in the later passages.  
 Hypertonicity induced increase in NFAT5 abundance and protein synthesis rate were found to 
be proportional to the increase in mRNA in MDCK [28] and mIMCD3 cells [27]. NFAT5 mRNA is 
expressed abundantly in chondrocytes throughout passages and is further induced by hypertonicity. 
However, we failed to show NFAT5 protein expression by Western blotting. Whether this is due to low 
protein abundance in our cells or technical issues like poor extraction efficiency of this very large 
transcription factor has to be elucidated in future experiments. 
 Hypertonicity induces cell shrinkage which may activate Na+, K+, or 2Cl- co-transport allowing 
cellular accumulation of NaCl and KCl. The beneficial effects on chondrogenic marker gene 
expression therefore could have been caused by accumulation of specific inorganic ions or specific 
channel activity rather than primarily tonicity-mediated effects. We used NMDG-Cl, a bulky substitute for 
small cations that is impermeable to almost all known channels [56], and sucrose to exclude sodium or 
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chloride specific effects. We were not able to detect any significant differences in gene expression patterns 
between the NaCl, NMDG-Cl or sucrose means of tonicity alteration (data not shown).  
 As our initial studies concerned adult human articular chondrocytes obtained from 
osteoarthritic knee joints, we aimed at eliminating interpretation bias due to the pathological state of 
these cells. Using identically challenged non-osteoarthritic cells (NHACs), we showed that these 
chondrocytes react similarly to the same order of tonicity with respect to our marker genes: 380 mOsm 
significantly delayed the phenotypical deterioration of NHACs as observed in control medium. This 
may imply that physiological tonicity, postulated to be around 380 mOsm for chondrocytes, is sensed 
by osteoarthritic and ‘normal’ cells in a similar fashion. We observed a slightly faster decrease in 
AGC1 and COL2 mRNA levels in P2 and P3 NHACs as compared to OA-HACs. Late stage 
osteoarthritic chondrocytes from fibrillated areas are dedifferentiated, flattened cells. The loss of a 
proper spherical shape as an integral part of the chondrocytes phenotype [57, 58] involves cytoskeletal 
changes [59]. Exposing these cells to physiological tonicity as re-differentiation stimulus likely induces 
a more enduring response as compared to spherical, normal’ chondrocytes. Cell based therapies 
using the latter are usually restricted to younger individuals after traumatic insults. Autologous 
chondrocyte implantation employing osteoarthritic cells may benefit relatively more from a hypertonic 
treatment protocol. 
  The precise molecular mechanism by which tonicity is sensed by cells is still poorly 
understood. Hypertonicity-increased NFAT5 mRNA abundances have been shown for other cell types 
[26-28].  NFAT5 is thus accepted as key transcription factor participating in the mammalian hypertonic 
stress response. Our study is the first showing the functional expression of NFAT5 in human articular 
chondrocytes. In both, osteoarthritic and ‘normal’ chondrocytes, cellular NFAT5 mRNA levels are 
increased by 380 mOsm. In addition, mRNA levels of generally accepted NFAT5 target genes, 
S100A4 and SLC6A12 [20, 60], were induced accordingly after hypertonic challenge, underscoring an 
involvement of NFAT5. It has recently been suggested that guanine nucleotide exchange factors near 
the plasma membrane may be activated through cytoskeleton changes or by changes in interactions 
with putative osmosensors at the cell membrane in other cells [61]. Sensation of such basic responses 
might not be different in chondrocytes than in other cells. Rho-type small G proteins [62] and p38 
kinases [63, 64] might act upstream of NFAT5 in chondrocytes, too. In IMCD cells, p38 MAPK 
signaling was recently also shown to be involved in the NFAT5-mediated hypertonic induction of the 
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osmo-sensitive [65, 66] serine-threonine protein kinase Sgk-1 [67, 68]. As p38 MAPK plays important 
roles in chondrocytes and seems to be necessary for NFAT5 expression [20], further experiments 
employing pharmacological inhibition or knockdown experiments in HACs will hopefully shed more 
light into this signaling cascade in chondrocytes.  
 Increase in NFAT5 mRNA is usually transient with a cell type depending time course and a 2- 
to 4-fold upregulation [26, 28] which fits with our data. NFAT5 mRNA abundance might rapidly 
increase upon hypertonic stress by a transient increase in its mRNA stability, mediated by its 5’-UTR 
[27]. Whether 380 mOsm is a sufficiently high tonicity to explain our increase in mRNA by this 
phenomenon or whether active transcription is involved, has to be addressed in other studies. 
Interestingly, very recently Tew et al. [69] showed that the mRNA of SOX9, an important regulator of 
COL2 expression, is stabilized by supra-physiological tonicity. Therefore, 380 mOsm might also 
directly contribute to SOX9 mRNA stability and abundance in our experiment, rather than elevating 
promoter activity. COL2 regulation could thus be an indirect effect of tonicity.  
 Interestingly, AGC1 seems to be more stably expressed in cultures maintained at 280 mOsm 
compared to 380 mOsm, with a lower overall expression in the former condition. Effects of tonicity on 
promoter activity and mRNA stability of AGC1 are incompletely understood. Other groups described 
the complexity of osmotic stress on gene expression [70, 71]. It is tempting to speculate that gene 
expression may be influenced by morphological changes between our conditions: while cells cultured 
at 380 mOsm are rather round, cells cultured in monolayer at 280 mOsm are rather flat and more 
fibroblast-like (see Figure 1). Although we did not investigate actin stress fiber formation in this study, 
they are usually more pronounced in fibroblastic cells and have been shown to suppress SOX9 mRNA 
levels in chondrocytes [50]. However, aggrecan expression has been reported to be influenced by 
both hyper- and hypo-tonicity [4, 8]. The promoter regions of both collagen type II and aggrecan 
contain a plethora of potential other binding sites for transcriptional enhancers and suppressors, such 
as SOX5/6 [72, 73], Barx2 [74], β-catenin [75], c-Maf [76], PIAS [77], TRAP230 [78], Bapx1 [79], and 
C/EBP and NF-kB [80]. Chondrogenic differentiation and SOX9-dependency of aggrecan and collagen 
expression may also be differentially modulated by these transcriptional co-factors under different 
tonicities. Interestingly, while SOX9 dependency of COL2A1 expression has been unequivocally 
shown, it may not actually be a key regulator of COL2A1 promoter activity in human adult articular 
chondrocytes [81]. Of note, the human aggrecan promoter sequence has been shown to contain a 
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conserved NFAT5 binding site [82]. In nucleus pulposus cells, SOX9 mediated aggrecan expression 
has recently been shown to critically depend on PI3K/AKT signalling [83]. Moreover, while high NaCl 
rapidly activates p38 MAPK, its action can be isoform specific and may exert opposing effects on 
NFAT5 [84], which in turn may influence COL2A1 and AGC1 transcription differently in a tonicity-
dependent manner. We are therefore currently looking into the underlying molecular mechanisms 
regulating aggrecan (AGC1) and collagen type II (COL2) expression in both conditions.  
 With respect to regenerative medical applications, the high-end hypertonic conditions used by 
Tew et al. can be considered a limitation of that study. In our hands, these tonicity levels (≥480 mOsm) 
induced chondrocyte death within 48 hours (Figure 1D) and are not likely applicable for chondrocyte 
expansion culture. To ensure sufficient cell numbers for cell-based repair techniques, proliferation 
capacity of the isolated chondrocytes should not be compromised. Cell numbers generally need to be 
increased during two passages (>4-10 times) for clinical application [85, 86]. We found that supra-
physiological conditions (480 and 580 mOsm) clearly compromised survival rates, which is in 
agreement with data by Racz et al. [17]. From our data, we conclude that about 380 mOsm is optimal 
for both isolation and in vitro expansion culture of HACs.   
NFAT5 knockdown down-regulates its own transcription by 75% and compromises target gene 
induction (Figure 5), being in line with a functionally active NFAT5 in chondrocytes. Constitutive 
homodimeric NFAT5 molecules encircle DNA rather independently of tonicity in solution [87], enabling 
NFAT5 to exert its biological activity over a wide tonicity range [88, 89]. It is thus reasonable to 
assume that NFAT5 activity is not generally compromised at 380 mOsm. However, other aspects are 
involved in the regulation of NFAT5 as well as its target genes. Like other proteins larger than 50kDa 
[90], NFAT5 dependents on nuclear localization and export sequences for its nuclear translocation [26, 
87, 90]. In most cells, NFAT5 is equally distributed between cytoplasm and nucleus at physiological 
tonicity (±300 mOsm), whereas at 500 mOsm most of it localizes to the nucleus [19, 26, 88].  
To demonstrate that the hypertonicity-induced chondrogenic marker expression was indeed 
mediated by NFAT5, we used RNAi to confirm that knockdown of NFAT5 significantly i) inhibited 
hypertonic induction of its own transcription as discussed before, (ii) suppressed the tonicity-mediated 
induction of known NFAT5 targets, and (iii) most importantly, eliminated the hypertonicity-mediated mRNA 
expression of chondrogenic marker genes (COL2, AGC1, SOX9 and COL1).    
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Conclusions  
 We have shown that isolation and expansion of adult human articular chondrocytes in culture 
medium of physiological tonicity (380 mOsm) improves chondrogenic marker expression and 
extracellular matrix production through NFAT5. We identified NFAT5 as a novel molecular target 
preserving chondrocytic marker expression. Our data provide valuable insights for the development of 
strategies for cell-based repair of chondral lesions and contributes to the understanding of 
mechanisms involving osteoarthritis.  
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Figure legends 
Figure 1. Hypertonic isolation and expansion of chondrocytes changes chondrocyte 
morphology. Representative images (200X) of chondrocytes cultured for 2 days at 280 (A), 380 (B), 
480 (C) and 580 (D) mOsm.  
 
Figure 2. Hypertonic isolation and expansion increased marker gene expression in OA-HACs. 
Relative expression of AGC1 (A), SOX9 (B), COL2 (C) and COL2:COL1 ratio (D) in primary (P0) and 
passaged (P1-P3) chondrocytes cultured at 380 mOsm compared to 280 mOsm. COL2 protein 
expression (E) and COL1 protein expression (F) in P0 and P1 OA-HACs are shown. Protein levels are 
normalized to α-Tubulin. All data are means ± SD, n = 12. Differences with cells cultured at 280 mOsm 
are indicated with * (p<0.05), ** (p<0.01) and *** (p<0.001). 
 
Figure 3. Hypertonic isolation and expansion increased chondrogenic marker expression in 
NHACs. Relative expression of AGC1 (A), SOX9 (B), COL2 (C) and COL2:COL1 ratio (D) in primary 
(P0) and passaged (P1-P3) NHACs cultured at 380 mOsm compared to cells cultured at 280 mOsm. 
COL2 (E) and COL1 (F) protein expression in P1 and P2 NHACs are shown and normalized to α-
Tubulin. Data are means ± SD; n = 6. Differences to 280 mOsm controls are indicated with * (p<0.05) 
and ** (p<0.01). 
 
Figure 4. Hypertonic conditions activate NFAT5 in OA-HACs. Relative expression of NFAT5 (A) and 
its target genes S100A4 (B) and SLC6A12 (C) in primary (P0) and passaged (P1 to P3) chondrocytes 
cultured at 380 mOsm compared to 280 mOsm. All data are means ± SD, n = 12. Differences are 
indicated with * (p<0.05), ** (p<0.01) and *** (p<0.001). 
 
Figure 5. NFAT5 knockdown inhibits hypertonicity-induced chondrogenic marker expression. (A) 
Relative expression of NFAT5 and its target genes S100A4 and SLC6A12 in transduced chondrocytes 
either expressing (NFAT5 shRNA) or not expressing (control) NFAT5-specific shRNAs, 24 hours after 
increasing tonicity to 380 mOsm. (B) Effects of NFAT5 knockdown on chondrogenic markers AGC1, 
SOX9, COL2 and COL1. All data are means ± SD, n = 6. Differences to cells transduced with control 
virus are indicated with * (p<0.05) and ** (p<0.01). 
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Table 1. Proliferation of chondrocytes isolated and cultured at 280, 380 and 480 mOsm 
Culture condition P0 P1 P2 P3 
280 mOsm 100 % 
(68 ± 28 hrs)  
100 % 
(89 ± 54 hrs)  
100 % 
(67 ± 48 hrs) 
100 % 
(57 ± 11 hrs) 
380 mOsm 113 ± 18 % 89 ± 25 % 99 ± 9 % 154 ± 41 % 
480 mOsm 675 ± 405 % * 180 ± 24 % * 168 ± 28 % * 165 ± 81 % * 
  
Displayed are relative doubling times in percentage (%) of cells cultured at 280 mOsm. All data are 
means ± SD. The absolute doubling time ± SD in hours is displayed in brackets. n=6 *p<0.05. mOsm, 
milliosmoles per kg of water. 
 
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
